Celcuity (Celcuity) 5-Year ROIIC % : -4,383.23% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Celcuity 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Celcuity's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -4,383.23%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Celcuity's 5-Year ROIIC % or its related term are showing as below:

CELC's 5-Year ROIIC % is ranked worse than
98.41% of 1380 companies
in the Biotechnology industry
Industry Median: -18.73 vs CELC: -4383.23

Celcuity 5-Year ROIIC % Historical Data

The historical data trend for Celcuity's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celcuity 5-Year ROIIC % Chart

Celcuity Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

5-Year ROIIC %

Get a 7-Day Free Trial

-505.12

-2,321.71

530.68

-4,383.23

Celcuity Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
5-Year ROIIC %	Get a 7-Day Free Trial															-	-	-	-4,383.23	-

Competitive Comparison of Celcuity's 5-Year ROIIC %

For the Biotechnology subindustry, Celcuity's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celcuity's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celcuity's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Celcuity's 5-Year ROIIC % falls into.

Celcuity 5-Year ROIIC % Calculation

Celcuity's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %	=	5-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	5-Year Incremental Invested Capital^**
	=	( -66.23 (Dec. 2023) - -7.933 (Dec. 2018) )	/	( 2.634 (Dec. 2023) - 1.304 (Dec. 2018) )
	=	-58.297	/	1.33
	=	-4,383.23%^***

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Celcuity (NAS:CELC) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Celcuity 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Celcuity's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Celcuity (Celcuity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » 5-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446

Website

https://www.celcuity.com

Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).

Executives

Richard E Buller	director	C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey	director	C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht	director	C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan	director, 10 percent owner, officer: Chief Executive Officer	16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon	director	CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing	director, 10 percent owner, officer: Chief Science Officer, VP	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne	officer: Chief Financial Officer	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin	director	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446